Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Open access
Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q.M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke, Roel, Rizvi, Naiyer A. · 2018 · Journal of Thoracic Oncology

Abstract

Introduction: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti–programmed death‐ligand 1 (PD‐L1) atezolizumab in advanced NSCLC selected by tumor cell (TC) or tumor‐infiltrating immune cell (IC) PD‐L1 expression. Methods: Patients with PD‐L1 TC2/3 (PD‐L1 staining on ≥5% of TC) or IC2/3 tumors (PD‐L1 staining on ≥5% of IC; determined by SP142 PD‐L1 immunohistochemistry assay) with paired fresh and archival histology samples were recruited into cohort 1 (chemotherapy‐naive/>6 months between adjuvant chemotherapy and recurrence), cohort 2 (≥ second‐line without brain metastases), or cohort 3 (≥ second‐line with treated brain metastases). Patients received 1200 mg atezolizumab on day 1 (21‐day cycles). Primary endpoint was investigator‐assessed modified Response Evaluation Criteria in Solid Tumors, objective response rate (Response Evaluation Criteria in Solid Tumors v1.1). Secondary endpoints were overall survival, progression‐free survival, duration of response, and safety. Results: Patients (N = 138) were enrolled (137 evaluable for response: cohort 1, n = 31; cohort 2, n = 93; and cohort 3, n = 13). Investigator‐assessed objective response rate was 32%, 21%, and 23% for cohorts 1, 2, and 3, respectively. Treatment‐related adverse events were reported in 81%, 67%, and 69% of patients, respectively, including grade 3–4 treatment‐related adverse events in 16%, 19%, and 15%, respectively. Moreover, 88.6% (86 of 97) paired baseline tumor samples had <5% change in TC/IC PD‐L1 expression over time. Conclusions: Atezolizumab monotherapy showed clinical activity in patients with NSCLC, including those with brain metastases; safety was consistent with previous trials. Atezolizumab has completed phase III monotherapy studies in second‐line. Front‐line trials are ongoing, confirming these favorable results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.05.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 159

Metadata

Authors
Spigel, D. R., Chaft, J. E., Gettinger, S., Chao, B. H., Dirix, L., Schmid, P., Chow, L. Q. M., Hicks, R. J., Leon, L., Fredrickson, J., Kowanetz, M., Sandler, A., Funke, R., & Rizvi, N. A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-11
Volume
13
Issue
11
Pages
1733-1742
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2807965874
Cited by
159
References
8
FWCI
6.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.